Latest Articles

Publication Date
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO - Citeline News & Insights

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO Citeline News & Insights

Published: Oct. 20, 2025, 10:35 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 20, 2025, 9:33 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0

Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0

Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com

Published: Oct. 20, 2025, 3:02 p.m.
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU - The Manila Times

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU The Manila Times

Published: Oct. 20, 2025, 12:36 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 20, 2025, noon
Could this lakeside mansion set a new Ballarat price record? - Herald Sun

Could this lakeside mansion set a new Ballarat price record? Herald Sun

Published: Oct. 20, 2025, 4:53 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace

Published: Oct. 20, 2025, 4:42 a.m.
Shaoyao Gancao Decoction: a comprehensive review of modern clinical applications and underlying pharmacological mechanisms.

Shaoyao Gancao Decoction, a classic formula from Zhang Zhongjing in the Han Dynasty, has the effects of regulating the function of the liver, relieving spasm and stopping pain. Traditionally, it …

Published: Oct. 20, 2025, midnight
Cellular Senescence in Endometrium: A Pivotal Regulator in Physiological Remodeling and Pathological Disorders.

As a highly dynamic tissue, the endometrium undergoes complex remodeling during the menstrual cycle and pregnancy. Recent studies have revealed that cellular senescence plays a pivotal role in both physiological …

Published: Oct. 20, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!